Nkarta, Inc. (NKTX) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -132.25M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 99.51M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-132.25M | (m) | (m) | $99.51M | (m) | (m) |
| 2026-03-31 | $-116.31M | (m) | (m) | $91.25M | (m) | (m) |
| 2025-12-31 | $-122.00M | $0.00 | (m) | $90.43M | (m) | (m) |
| 2025-09-30 | $-121.96M | (m) | (m) | $88.28M | (m) | (m) |
| 2025-06-30 | $-128.47M | (m) | (m) | $93.33M | (m) | (m) |
| 2025-03-31 | $-132.00M | (m) | (m) | $95.68M | (m) | (m) |
| 2024-12-31 | $-128.19M | $0.00 | (m) | $96.74M | (m) | (m) |
| 2024-09-30 | $-128.46M | (m) | (m) | $96.94M | (m) | (m) |
| 2024-06-30 | $-123.96M | (m) | (m) | $93.88M | (m) | (m) |
| 2024-03-31 | $-130.10M | (m) | (m) | $95.88M | (m) | (m) |
| 2023-12-31 | $-131.65M | (m) | (m) | $96.77M | (m) | (m) |
| 2023-09-30 | $-135.45M | (m) | (m) | $100.30M | (m) | (m) |
| 2023-06-30 | $-136.42M | (m) | (m) | $101.54M | (m) | (m) |
| 2023-03-31 | $-127.17M | (m) | (m) | $97.46M | (m) | (m) |
| 2022-12-31 | $-118.95M | (m) | (m) | $90.90M | (m) | (m) |
| 2022-09-30 | $-106.86M | (m) | (m) | $81.35M | (m) | (m) |
| 2022-06-30 | $-99.03M | (m) | (m) | $74.53M | (m) | (m) |
| 2022-03-31 | $-93.05M | (m) | (m) | $69.44M | (m) | (m) |
| 2021-12-31 | $-86.43M | (m) | (m) | $63.41M | (m) | (m) |
| 2021-09-30 | $-81.54M | (m) | (m) | $57.38M | (m) | (m) |
| 2021-06-30 | $-72.86M | (m) | (m) | $50.59M | (m) | (m) |
| 2021-03-31 | $-61.58M | (m) | (m) | $42.50M | (m) | (m) |
| 2020-12-31 | $-51.51M | (m) | (m) | $36.22M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-22.35M | $115.00K | (m) | $17.22M | (m) | -19433.91% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |